{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-006688","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.254291+00:00","generated_at":"2026-06-27T05:11:29.565628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MannKind reports 2021 revenue $75.4M, +16%; Afrezza Q4 record $11.3M; net loss widens","bullets":["Total revenues 2021: $75.4M (+16% vs 2020); Afrezza net revenue $39.2M (+21% YoY)","Q4 Afrezza net revenue $11.3M (+13% vs Q4 2020); collaborations revenue $1.2M","Cash and investments $260.7M at Dec 31, 2021 vs $67.2M a year ago; includes $230M convertible note and ~$100M sale-leaseback","Full-year net loss $80.9M ($0.32/sh) vs $57.2M ($0.26/sh) in 2020; non-GAAP loss $61.7M ($0.25/sh)","Tyvaso DPI PDUFA deadline extended to May 2022; clofazimine Phase 1 trial commenced in 1Q 2022"],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-006688","json":"https://secwatch.observer/filing/0001564590-22-006688.json","markdown":"https://secwatch.observer/filing/0001564590-22-006688.md","text":"https://secwatch.observer/filing/0001564590-22-006688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000156459022006688/0001564590-22-006688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000156459022006688/mnkd-8k_20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:11:29.565628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}